In a new study it was shown that smoking doubles the chances that a prostate cancer survivor will have the cancer spread and that he would die from the cancer. Study co-author Dr. Michael Zelefsky, Vice Chair of Clinical Research in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center said, "Basically we [...]
In a recent publication it was suggested that radiographic progression-free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC) was highly consistent and highly associated with overall survival. This reproducible quantitative find could have implications for the interim measurement of treatment response in future studies, according to Dr. Michael J. Morris of Memorial Sloan [...]
It was recently discovered that if hormone therapy (ADT) is added to radiation cancer deaths are lowered by nearly 50 % in men with locally advanced prostate cancer aged 76 to 85 compared to men who only received hormone therapy. Prior studies have shown that 40% of men with aggressive prostate cancers are treated with [...]
Liver metastases are uncommon in men with castrate resistant prostate cancer (CRPC). Having liver metastases is associated with more serious disease and shorter survival. How to treat men with liver metastases is still not very clear. It is felt that more active treatment might benefit these men. A standard regimen for treating gastric cancer is [...]
It isn’t here yet, but it very much is here! What am I talking about? Circulating tumor cells (CTCs) are going to become a clear winner for us as the concept of using them finds its way into commercialization. Metastatic castration resistant prostate cancer (mCRPC) is difficult to evaluate using our less than stellar conventional [...]